Future of Oligonucleotide Synthesis Market Global Forecast to 2022

The growth of this market is mainly driven by the increasing research activities in the pharma and biotech sectors and the rising demand for innovative diagnostic and therapeutic techniques.

The global oligonucleotide synthesis market is valued at USD 1.33 Billion in 2016 and is projected to reach USD 2.46 Billion by 2022, at a CAGR of 10.9%. The base year considered for the study is 2016 and the forecast period is from 2017 to 2022.

Download FREE Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=200829350

This report segments the market into product, application, end user, and region

Target Audience for this Report:

• Life science instrumentation and reagent companies
• Pharmaceutical and biotechnology companies
• Hospitals and clinics
• Academic researchers and government research organizations
• Private research institutes
• Custom oligonucleotide service providers
• Contract manufacturing organizations (CMOs)
• Oligonucleotide equipment manufacturers
• Contract research organizations (CROs)
• Market research and consulting firms
• Venture capitalists

The oligonucleotide synthesis market is highly competitive with the presence of several small and big players. 

Prominent players in the market include Integrated DNA Technologies (IDT) (US), Sigma-Aldrich Corporation (US) (part of Merck KGaA), Eurogentec (Belgium), Eurofins Genomics (Germany), Agilent Technologies (US), Thermo Fisher Scientific (US), BioAutomation (US), LGC Biosearch Technologies (US), GeneDesign (Japan), GE Healthcare (US), TriLink BioTechnologies (US), GenScript (China), Nitto Denko Avecia (US), ATDBio (UK), Bio-Synthesis (US), IBA GmbH (Germany), Gene Link (US), and AITbiotech Pte. (Singapore)

To Know More @ https://www.marketsandmarkets.com/Market-Reports/oligonucleotide-synthesis-market-200829350.html